Camelid Antibodies Modulating Activated Protein C Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bleeding, ischemia, sepsis, and cancer associated with the protein C pathway face challenges such as immunogenicity, efficacy, and specificity, particularly in modulating the anticoagulant and cytoprotective functions of activated protein C (APC).
Innovation Solution
Development of isolated antibodies that specifically bind to activated protein C (APC) with minimal binding to unactivated protein C (PC), thereby inhibiting or enhancing the anticoagulant and cytoprotective functions of APC as needed for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies are used to treat bleeding conditions by inhibiting APC, then anticoagulant function is reduced, but immunogenicity and specificity are problematic
Solution Approach 1:
The patent changes the structural parameters of the antibody by using camelid VHH domains instead of conventional mammalian antibodies. This structural parameter change reduces immunogenicity while maintaining therapeutic efficacy, directly resolving the contradiction between reliability and harmful factors.
Solution Approach 2:
The patent applies local quality by designing antibodies with specific CDR3 sequences that target particular epitopes on APC. This localized specificity ensures high-affinity binding to the target while minimizing off-target effects and immunogenic responses.
2Adaptability or versatility
If antibodies bind to both activated and unactivated protein C, then broader coverage is achieved, but specificity for modulating APC functions is reduced
Solution Approach 1:
The patent employs local quality by designing CDR3 regions with specific amino acid sequences that recognize unique structural features of activated protein C. This localized specificity allows the antibody to distinguish between APC and unactivated protein C, achieving high binding specificity.
Solution Approach 2:
The patent segments the antibody structure into distinct functional regions, particularly emphasizing the CDR3 hypervariable region. This segmentation allows independent optimization of the CDR3 sequence for APC-specific recognition while keeping other regions standardized.
3Reliability
If high concentrations of APC are used to treat bleeding, then anticoagulant effect is enhanced, but risk of excessive bleeding increases
Solution Approach 1:
The patent uses antibodies as intermediaries that selectively bind to and modulate APC activity. Instead of directly administering high concentrations of APC, the antibody intermediary provides controlled, specific inhibition of APC's anticoagulant function, achieving therapeutic effect with reduced risk.
Solution Approach 2:
The patent changes the therapeutic parameter from direct APC concentration control to antibody-mediated APC activity modulation. This parameter change allows precise control over APC function with a wider safety margin, reducing the risk of excessive bleeding while maintaining efficacy.
Data Source
AI summary
The present invention provides antibodies against activated protein C (APC). Certain disclosed antibodies inhibit the anticoagulant activity of APC while preserving its beneficial cytoprotective functions. The present invention also provides nucleic acids, vectors, and host cells for producing the antibodies disclosed herein, as well as methods of using the antibodies to treat medical conditions such as bleeding, sepsis, and inflammation.